<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url><loc>https://www.pharmaradar360.com/article/9164e8a3ea4188d8</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-11T00:00:00.000Z</news:publication_date><news:title>Pharma Research &amp; Development</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/a6d04440b8d67e7b</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-11T00:00:00.000Z</news:publication_date><news:title>Latest Research</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/19f59684ccd74cc6</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-11T00:00:00.000Z</news:publication_date><news:title>Geliose Mobility, an IIT Delhi incubated startup, launches ‘HOPE’, an affordable electric scooter for last mile delivery and personal commute</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/2f248d6ce8bb4ceb</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-10T21:04:26.000Z</news:publication_date><news:title>Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 202</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/98bd3f68fba7139f</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-10T20:53:38.000Z</news:publication_date><news:title>Predicting T Cell Recognition: New Insights from Large-Scale Activation Data</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/cd5efb6e2cb34c46</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-10T20:00:36.000Z</news:publication_date><news:title>GAP Nail™ Endo-Exo Medullary System</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/830b8ec3b42c913f</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-10T16:00:00.000Z</news:publication_date><news:title>Decision: Advertising investigations: March 2026</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/c66db7daf1cc0ecf</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-10T16:00:00.000Z</news:publication_date><news:title>Kennedy expands ACIP function, membership criteria</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/5b715e12d81ebb52</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-10T15:30:00.000Z</news:publication_date><news:title>日本新薬とイクスフォレストセラピューティクス RNA構造を標的とした創薬研究に関する契約を締結</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/d9b6e6f4728831a0</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-10T15:08:25.000Z</news:publication_date><news:title>Virtual Twins: What They Are &amp; Their Impact in Life Sciences</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/111274929215e1bb</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-10T14:00:00.000Z</news:publication_date><news:title>Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 April 2026</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/4d9ceb5c4c37ee01</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-10T12:35:30.000Z</news:publication_date><news:title>eXoZymes CCO, Damien Perriman, outlines NCTx strategy and the commercial path for cell-free biomanufacturing on Grow Everything podcast</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/7a216e651106fb9b</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-10T12:29:45.000Z</news:publication_date><news:title>ANMAT concluyó el proceso para la baja definitiva de las firmas HLB PHARMA GROUP S.A. y LABORATORIOS RAMALLO S.A.</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/3c0f8e692dacdbe3</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-10T10:00:00.000Z</news:publication_date><news:title>Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002)</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/e166fe404610756c</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-10T08:00:00.000Z</news:publication_date><news:title>「デジタルトランスフォーメーション銘柄（DX銘柄）2026」選定のお知らせ</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/f926d17dcb34b0fa</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-10T08:00:00.000Z</news:publication_date><news:title>Chugai Selected as &amp;ldquo;Digital Transformation Stocks (DX Stocks) 2026&amp;rdquo</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/4ffded644d4b86c0</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-10T07:00:00.000Z</news:publication_date><news:title>A Clínic-IDIBAPS study discovers that nanoparticles with DNA enhance the effect of immunotherapy against cancer</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/4d6a4308a4bc8473</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-10T03:15:00.000Z</news:publication_date><news:title>Differences in cells’ protein factories may help explain human diversity</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/5a40dbb5cfb5094b</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-10T03:00:00.000Z</news:publication_date><news:title>[SHINSA]Considerations for clinical development of intravenous formulations containing the same active ingredient as oral products for patients who are temporarily unable to receive oral administration in epilepsy treatment （Early consideration） posted</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/9103b3a1cebe5467</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-10T01:30:00.000Z</news:publication_date><news:title>Alexion data at 2026 AAN Annual Meeting reflects industry-leading portfolio and commitment to enhancing care across rare diseases</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/3dfd85876dbf074e</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-10T01:15:26.000Z</news:publication_date><news:title>Analysis of NPC1 Genotypes: Findings From the US Arimoclomol Expanded Access Program for Niemann-Pick Disease Type C</news:title></news:news></url><url><loc>https://www.pharmaradar360.com/article/09ccb62990dfe934</loc><news:news><news:publication><news:name>PharmaRadar360</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-10T01:00:00.000Z</news:publication_date><news:title>Why do anglerfish have glowing lures? It might be sex</news:title></news:news></url></urlset>